A pioneering gene therapy has successfully slowed the progression of Huntington’s disease by 75% in patients after three years.

Cell and gene therapies (CGTs) represent the cutting edge of drug discovery. 1 These are amongst the most advanced medical treatments, specifically designed to correct the root genetic cause of an ...

The Cell and Gene Therapy Catapult and pHion Therapeutics announced an exclusive licence agreement for pHion’s proprietary RALA technology for ex-vivo applications. The agreement builds upon the ...

Gene therapy for Huntington’s disease, a rare degenerative brain disorder, has succeeded for the first time in the UK.

Researchers in the lab of Hans-Peter Kiem, MD, PhD, at Fred Hutch Cancer Center have devised a method that could one day treat genetic hematologic disorders by correcting how the body makes blood ...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) announced today that the Company presented preclinical data from its novel adeno-associated virus (AAV) gene therapy ...

Over the last 15 years, I have witnessed how cell and gene therapy (CGT) has evolved in many ways, spanning from research and development to manufacturing. Breakthroughs such as CAR-T and gene therapy ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

One oral presentation and five poster presentations will highlight exciting progress in AskBio’s pipeline and advancements in ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT ...

Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy ...